SCHEMBL2952084

SCHEMBL2952084

Cc1ccc(-c2nncc3cc(Cl)ccc23)c(C)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 4/20 0.39
NOTUM Q6P988 1/20 0.39
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
KMT2A Q03164 1/20 0.39
PTGDR2 Q9Y5Y4 1/20 0.39
CRHR1 P34998 1/20 0.38
MAPK14 Q16539 5/20 0.38
KIT P10721 3/20 0.38
MAPK9 P45984 1/20 0.38
MAPK10 P53779 1/20 0.38
POLB P06746 1/20 0.36
CYP3A4 P08684 1/20 0.36
HSD11B1 P28845 1/20 0.36
MAPT P10636 1/20 0.35
C1S P09871 1/20 0.34
HSP90AB1 P08238 2/20 0.34
FLT1 P17948 1/20 0.34
LCK P06239 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL600322 0.86 MAPK14 (0.46) SCN9ANOTUMCRHR1MAPK14FLT1
SCHEMBL2945468 0.84 MAPK14 (0.48) SCN9AKDM4EMEN1ALDH1A1KMT2A
SCHEMBL2952583 0.75 MAPK14 (0.55) MAPK14KITMAPK9MAPK10CYP3A4
SCHEMBL2945976 0.71 MAPK14 (0.60) ALDH1A1MAPK14KITMAPK9MAPK10
SCHEMBL6615543 0.70 FLT3 (0.44) SCN9AKDM4EMEN1ALDH1A1KMT2A
SCHEMBL2944602 0.70 MAPK14 (0.48) SCN9AKDM4EMEN1ALDH1A1KMT2A
SCHEMBL2955292 0.69 MAPK14 (0.52) MAPK14KITMAPK9MAPK10LCK
SCHEMBL2951955 0.69 MAPK14 (0.52) MAPK14KITMAPK9MAPK10LCK
SCHEMBL30317642 0.69 FLT1 (0.39) ALDH1A1POLBC1SFLT1EGFR
SCHEMBL398775 0.69 FLT1 (0.39) ALDH1A1POLBC1SFLT1EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1856058-B1 PHTHALAZINE, AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AND METHODS OF USE AMGEN INC (US) 2014-09-03 EP disclosed
US-7759337-B2 Phthalazine compounds and methods of use AMGEN INC. (US) 2010-07-20 US disclosed
EP-1856058-A2 PHTHALAZINE, AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AND METHODS OF USE Amgen Inc. (US) 2007-11-21 EP disclosed
WO-2006094187-A2 PHTHALAZINE, AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AND METHODS OF USE AMGEN INC (US) 2006-09-08 WO disclosed
US-20060199817-A1 Phthalazine, aza- and diaza-phthalazine compounds and methods of use AMGEN INC. (US) 2006-09-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060199817-A1 Phthalazine, aza- and diaza-phthalazine compounds and methods of use DAPK2, CDK2, DAPK1 SCN9A 4568/4885NOTUM 4088/4885KDM4E 929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.